-
Mashup Score: 7
The combination appears more likely than either agent alone to reduce risk of early COVID-19 symptoms worsening and requiring hospitalization.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0Fluvoxamine May Not Improve COVID-19 Outcomes - 1 year(s) ago
Fluvoxamine, a drug approved to treat obsessive-compulsive disorder, showed promise in some trials as a potentially inexpensive treatment f…
Source: alert.psychnews.orgCategories: Latest Headlines, PsychiatryTweet-
#Fluvoxamine, a drug approved to treat #OCD, showed promise in some trials as a potentially inexpensive treatment for #COVID19. Yet a study found that the drug may be no more beneficial for patients than a placebo. https://t.co/gYKWROmieF #PsychTwitter #MedTwitter #MentalHealth
-
-
Mashup Score: 0What are the benefits and harms of fluvoxamine for adults with mild COVID‐19? - Ciapponi, Agustín - 2022 | Cochrane Library - 2 year(s) ago
Cochrane Clinical Answers Clinical Answer: Low‐certainty evidence suggests that for adults with mild COVID‐19, fluvoxamine may slightly reduce all‐cause mortality at day 28 (23 vs 33 per 1000 people, all results on average) and may reduce admission to hospital or death (a composite outcome; 73 vs 131 per 1000 people) when compared with placebo. However, the 95% confidence interval is compatible…
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet-
What are the benefits and harms of #fluvoxamine for adults with mild #COVID19? ➡️ Read the new @CochraneLibrary Clinical Answer: https://t.co/ndeFTqY5h5 📃 Read the plain language summary and full review: https://t.co/yUhBsedCZh #CochraneClinicalAnswers https://t.co/C9iNuxAkf8
-
-
Mashup Score: 0
This systematic review and meta-analysis examines randomized clinical trial evidence for fluvoxamine to prevent hospitalization of patients with COVID-19.
Source: jamanetwork.comCategories: Infectious Disease, Latest HeadlinesTweet-
Another interesting low cost generic drug is #fluvoxamine which at a dose of 100mg 2x/daily has a modest clincial benefit. Relevant in locales without access to MAb and paxlovid. No the 50mg 2x/day dose does not have benefit. https://t.co/00IOUndQ2d https://t.co/nyZzchmz5L
-
-
Mashup Score: 3NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals - 2 year(s) ago
NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
Source: www.jwatch.orgCategories: Healthcare Professionals, Latest HeadlinesTweet-
Laying Some Spurious #COVID19Treatments to Rest CT Bramante MD et al. https://t.co/g60DmC1m0h @NEJM #Ivermectin #Metformin #Fluvoxamine https://t.co/kCz7OsUDNN
-
-
Mashup Score: 33Time to Stop Using Ineffective Covid-19 Drugs | NEJM - 2 year(s) ago
Editorial from The New England Journal of Medicine — Time to Stop Using Ineffective Covid-19 Drugs
Source: New England Journal of MedicineCategories: Expert Picks, Latest HeadlinesTweet-
Time to Stop Using Ineffective #Covid19 Drugs Like #Ivermectin and #fluvoxamine | New England Journal of Medicine https://t.co/rEyPmvdgDF
-
-
Mashup Score: 151. Study Introduction - 2 year(s) agoSource: YouTubeCategories: Infectious Disease, Latest HeadlinesTweet
-
Let's talk about the Covid-Out trial that @BramanteCarolyn led from @umnmedschool as early treatment of #covid19. https://t.co/WtLoV6pJP2 This trial tested #metformin, #ivermectin, or low dose #fluvoxamine in a 3x2 factorial design where volunteers received 2 meds or placebos.
-
-
Mashup Score: 1
The need for safe and effective treatment against the various strains of COVID-19 increase, and investigators continue to assess various pharmacologic options.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#ICYMI: "The authors concluded that #fluvoxamine may have a place in therapy for the management of outpatient, unvaccinated adults with #COVID19 infection to reduce the progression to hospitalization." https://t.co/TOsqicjUsg
-
-
Mashup Score: 1
The need for safe and effective treatment against the various strains of COVID-19 increase, and investigators continue to assess various pharmacologic options.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
NEW from our print edition: Amidst the need for treatments effective against #COVID19 variants of concern, #Fluvoxamine has the potential to reduce COVID-19 hospitalizations. https://t.co/85HfFCX7wX
-
-
Mashup Score: 4What’s the Evidence for Fluvoxamine in COVID-19? - 2 year(s) ago
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
Source: The Scientist Magazine®Categories: Infectious Disease, Latest HeadlinesTweet-
A good write up by @TheScientistLLC @ce_offord on different physicians perspectives of #fluvoxamine and the FDA EUA decline. For those wanting outpatient Rx to show a mortality benefit, the US RCTs I have been involved with have a 0.1% mortality. https://t.co/cl64XSDy4B
-
Platform trial of several drugs repurposed for #COVID19 finds promise in the combination of oral #fluvoxamine and inhaled #budesonide https://t.co/Z64TdJfMAi